Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)RECK, Martin.Anticancer research. 2005, Vol 25, Num 3A, pp 1501-1506, issn 0250-7005, 6 p.Article

Examining the safety profile of angiogenesis inhibitors: implications for clinical practiceRECK, Martin.Targeted oncology. 2010, Vol 5, Num 4, pp 257-267, issn 1776-2596, 11 p.Article

Gefitinib ('Iressa'): a new therapy for advanced non-small-cell lung cancerRECK, Martin; GATZEMEIER, Ulrich.Respiratory medicine. 2005, Vol 99, Num 3, pp 298-307, issn 0954-6111, 10 p.Article

Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancerRECK, Martin; CRINO, Lucio.Lung cancer. 2009, Vol 63, Num 1, pp 1-9, issn 0169-5002, 9 p.Article

Benefit in lung function improvement and side-effect profile of long-term responders : An analysis of 14 NSCLC patients treated for at least 9 months with gefitinibRECK, Martin; GATZEMEIER, Ulrich.Lung cancer. 2005, Vol 50, Num 1, pp 107-114, issn 0169-5002, 8 p.Article

Pemetrexed-cisplatin combination in mesotheliomaRECK, Martin; GATZEMEIER, Ulrich.Expert review of anticancer therapy. 2005, Vol 5, Num 2, pp 231-237, issn 1473-7140, 7 p.Article

Characteristics, treatment patterns and outcomes of patients with small cell lung cancer—A retrospective single institution analysisHERMES, Andreas; WASCHKI, Benjamin; GATZEMEIER, Ulrich et al.Lung cancer. 2011, Vol 71, Num 3, pp 363-366, issn 0169-5002, 4 p.Article

Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancerHUBER, Rudolf M; RECK, Martin; THOMAS, Michael et al.The European respiratory journal. 2013, Vol 42, Num 4, pp 1119-1133, issn 0903-1936, 15 p.Article

Hyponatremia as prognostic factor in small cell lung cancer ― A retrospective single institution analysisHERMES, Andreas; WASCHKI, Benjamin; RECK, Martin et al.Respiratory medicine. 2012, Vol 106, Num 6, pp 900-904, issn 0954-6111, 5 p.Article

Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer: A retrospective single institution analysisHERMES, Andreas; GATZEMEIER, Ulrich; WASCHKI, Benjamin et al.Respiratory medicine. 2010, Vol 104, Num 12, pp 1937-1942, issn 0954-6111, 6 p.Article

Targeted therapies for non-small cell lung cancerDEMPKE, Wolfram C. M; SUTO, Tamas; RECK, Martin et al.Lung cancer. 2010, Vol 67, Num 3, pp 257-274, issn 0169-5002, 18 p.Article

A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignanciesTWELVES, Chris; RECK, Martin; ANTHONEY, Alan et al.Cancer chemotherapy and pharmacology. 2003, Vol 52, Num 4, pp 277-281, issn 0344-5704, 5 p.Article

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialGARON, Edward B; CIULEANU, Tudor-Eliade; CZYZEWICZ, Grzegorz et al.Lancet (British edition). 2014, Vol 384, Num 9944, pp 665-673, issn 0140-6736, 9 p.Article

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non―Small-Cell Lung Cancer: A Phase III TrialSCAGLIOTTI, Giorgio V; KRZAKOWSKI, Maciej; PAPAI, Zsolt S et al.Journal of clinical oncology. 2012, Vol 30, Num 17, pp 2070-2078, issn 0732-183X, 9 p.Article

Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST studyHEIGENER, David F; WU, Yi-Long; VAN ZANDWIJK, Nico et al.Lung cancer. 2011, Vol 74, Num 2, pp 274-279, issn 0169-5002, 6 p.Article

Chemotherapy in stage-IV NSCLCRECK, Martin; GATZEMEIER, Ulrich.Lung cancer. 2004, Vol 45, pp S217-S222, issn 0169-5002, SUP2Conference Paper

Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancerHOTTA, Katsuyuki; SUZUKI, Etsuji; HISAMOTO-SATO, Akiko et al.Lung cancer. 2013, Vol 79, Num 1, pp 20-26, issn 0169-5002, 7 p.Article

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non-Small-Cell Lung CancerSCAGLIOTTI, Giorgio; NOVELLO, Silvia; AREN, Osvaldo et al.Journal of clinical oncology. 2010, Vol 28, Num 11, pp 1835-1842, issn 0732-183X, 8 p.Article

Spectroscopy on laser induced plasma in cavitation bubblesKOCH, Sandra; RECK, Martin; NEU, Walter et al.Proceedings of SPIE, the International Society for Optical Engineering. 2010, Vol 7376, issn 0277-786X, isbn 978-0-8194-7652-4, 73761F.1-73761F.10Conference Paper

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST) : a randomised phase III trial. CommentaryCULLEN, Michael; THATCHER, Nicholas; SELLERS, Mark V et al.Lancet (British edition). 2008, Vol 372, Num 9652, issn 0140-6736, 1785-1786, 1809-1818 [12 p.]Article

Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in Patients with small-cell lung cancerRECK, Martin; VON PAWEL, Joachim; MACHA, Hans-Nicolas et al.Journal of the National Cancer Institute. 2003, Vol 95, Num 15, pp 1118-1127, issn 0027-8874, 10 p.Article

Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancerPALLAUD, Celine; RECK, Martin; JUHASZ, Erzsebet et al.Lung cancer. 2014, Vol 86, Num 1, pp 67-72, issn 0169-5002, 6 p.Article

Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancerMERIMSKY, Ofer; CHENG, Chi-Kin; SIU-KIE AU, Joseph et al.Oncology reports. 2012, Vol 28, Num 2, pp 721-727, issn 1021-335X, 7 p.Article

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non―Small-Cell Lung CancerLARA, Primo N; DOUILLARD, Jean-Yves; FANDI, Abderrahim et al.Journal of clinical oncology. 2011, Vol 29, Num 22, pp 2965-2971, issn 0732-183X, 7 p.Article

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung CancerSOCINSKI, Mark A; SMIT, Egbert F; JASSEM, Jacek et al.Journal of clinical oncology. 2009, Vol 27, Num 28, pp 4787-4792, issn 0732-183X, 6 p.Article